



## **EFPIA Disclosure Code 2021 Self-Certification Scheme**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Servier works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs) to learn from their knowledge and experience of patient's condition that is able to provide a true picture of what it is like to live with a specific condition, how care is delivered, how that impacts on them, their careers and families and how medicines and other treatments can change their quality of life and meet their needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards. Despite the exceptional circumstances related to COVID-19, Member Companies made their best efforts to disclose the relevant information for 2020.

Except in countries where disclosure is prescribed by laws, Servier hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2020 have been reported in application of the EFPIA Code following key principles:

### **Disclosure quality**

Servier certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

**Methodology used for the collection and organisation of ToVs is in line with the EFPIA Code's requirements and applicable codes**

Servier certifies that:

- Data collection complies with the requirements of the EFPIA Code;
- Actions are taken to ensure individual disclosure for HCPs, HCOs and POs' transfers of values (each as defined in the EFPIA Code).

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons**

Servier certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO/PO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO/PO (where applicable) are being disclosed in the aggregate.

**Ensuring compliance with Data Privacy Obligations**

Servier certifies that its disclosure complies with the Data Privacy obligations.

Date: July 22, 2021

Name of signatory: Olivier LAUREAU

Position in the Company: CEO

Signature:

